Date: 2013-06-19
Type of information: Initiation of development program
phase: preclinical
Announcement: selection of a development candidate
Company: Aurigene (India) Debiopharm Group (Switzerland)
Product: Debio 0617B
Action
mechanism: Debio 0617B is a novel small molecule targeting an undisclosed oncology pathway.
Disease:
Therapeutic area: Cancer - Oncology
Country:
Trial details:
Latest
news: * On June 19, 2013, Aurigene Discovery Technologies, a Bangalore-based biotech focusing on small molecule and peptide drug discovery and Debiopharm Group™ (Debiopharm), a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, have announced the successful nomination of a development candidate, Debio 0617B. Debio 0617B is expected to enter clinical development in Q4 2014.
Debiopharm and Aurigene have been collaborating on several discovery projects since 2006. The companies have signed an exclusive worldwide license agreement, to develop and commercialize Debio 0617B in 2012. The teams have successfully identified and validated the development candidate that meets the target molecular profile for a unique, first-in-class mechanism of action that targets several potential unmet needs in oncology.
